HLB Life Science Co., Ltd. (067630.KQ)
KRW 9780.0
(-1.81%)
KRW 9780.0
(-1.81%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 192.28 Billion KRW | 9.43% |
| 2022 | 175.72 Billion KRW | 626.5% |
| 2021 | 24.18 Billion KRW | -38.69% |
| 2020 | 39.45 Billion KRW | -44.05% |
| 2019 | 70.51 Billion KRW | -57.27% |
| 2018 | 165.01 Billion KRW | 257.24% |
| 2017 | 46.19 Billion KRW | -16.0% |
| 2016 | 54.99 Billion KRW | 227.27% |
| 2015 | 16.8 Billion KRW | -15.78% |
| 2014 | 19.95 Billion KRW | -46.35% |
| 2013 | 37.19 Billion KRW | -4.21% |
| 2012 | 38.82 Billion KRW | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 196.71 Billion KRW | 2.3% |
| 2024 Q2 | 134.27 Billion KRW | -31.74% |
| 2023 Q1 | 176.85 Billion KRW | 0.65% |
| 2023 Q3 | 189.51 Billion KRW | 7.22% |
| 2023 Q4 | 192.28 Billion KRW | 1.46% |
| 2023 FY | 192.28 Billion KRW | 9.43% |
| 2023 Q2 | 176.75 Billion KRW | -0.06% |
| 2022 Q3 | 188.61 Billion KRW | 78.57% |
| 2022 FY | 175.72 Billion KRW | 626.5% |
| 2022 Q4 | 175.72 Billion KRW | -6.83% |
| 2022 Q2 | 105.62 Billion KRW | 440.32% |
| 2022 Q1 | 19.54 Billion KRW | -19.18% |
| 2021 Q4 | 24.18 Billion KRW | -19.83% |
| 2021 Q3 | 30.17 Billion KRW | -25.47% |
| 2021 FY | 24.18 Billion KRW | -38.69% |
| 2021 Q1 | 35.95 Billion KRW | -8.87% |
| 2021 Q2 | 40.48 Billion KRW | 12.6% |
| 2020 Q3 | 41.65 Billion KRW | -34.45% |
| 2020 Q4 | 39.45 Billion KRW | -5.29% |
| 2020 Q1 | 70.56 Billion KRW | 0.08% |
| 2020 Q2 | 63.55 Billion KRW | -9.94% |
| 2020 FY | 39.45 Billion KRW | -44.05% |
| 2019 Q1 | 94.86 Billion KRW | -42.51% |
| 2019 FY | 70.51 Billion KRW | -57.27% |
| 2019 Q4 | 70.51 Billion KRW | 7.24% |
| 2019 Q3 | 65.74 Billion KRW | -50.09% |
| 2019 Q2 | 131.71 Billion KRW | 38.85% |
| 2018 Q4 | 165.01 Billion KRW | 14.6% |
| 2018 FY | 165.01 Billion KRW | 257.24% |
| 2018 Q3 | 143.99 Billion KRW | 19.24% |
| 2018 Q2 | 120.75 Billion KRW | -15.77% |
| 2018 Q1 | 143.35 Billion KRW | 210.36% |
| 2017 Q1 | 54.72 Billion KRW | -0.5% |
| 2017 Q2 | 56.17 Billion KRW | 2.66% |
| 2017 Q3 | 58.79 Billion KRW | 4.67% |
| 2017 Q4 | 46.19 Billion KRW | -21.44% |
| 2017 FY | 46.19 Billion KRW | -16.0% |
| 2016 Q4 | 54.99 Billion KRW | 0.2% |
| 2016 FY | 54.99 Billion KRW | 227.27% |
| 2016 Q3 | 54.88 Billion KRW | 270.21% |
| 2016 Q2 | 14.82 Billion KRW | -5.38% |
| 2016 Q1 | 15.66 Billion KRW | -6.76% |
| 2015 Q2 | 24.4 Billion KRW | 24.27% |
| 2015 Q1 | 19.63 Billion KRW | -1.58% |
| 2015 FY | 16.8 Billion KRW | -15.78% |
| 2015 Q3 | 24.71 Billion KRW | 1.28% |
| 2015 Q4 | 16.8 Billion KRW | -32.02% |
| 2014 Q1 | 25.44 Billion KRW | -31.59% |
| 2014 Q4 | 19.95 Billion KRW | -23.66% |
| 2014 FY | 19.95 Billion KRW | -46.35% |
| 2014 Q3 | 26.13 Billion KRW | -15.55% |
| 2014 Q2 | 30.94 Billion KRW | 21.65% |
| 2013 Q2 | 37.78 Billion KRW | 3.79% |
| 2013 Q3 | 35.24 Billion KRW | -6.72% |
| 2013 Q4 | 37.19 Billion KRW | 5.51% |
| 2013 FY | 37.19 Billion KRW | -4.21% |
| 2013 Q1 | 36.4 Billion KRW | -6.23% |
| 2012 FY | 38.82 Billion KRW | 0.0% |
| 2012 Q3 | 39.48 Billion KRW | 0.0% |
| 2012 Q4 | 38.82 Billion KRW | -1.67% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|